Subvenite (Orange) (Lamotrigine) Patent Expiration, LOE Window & CMS Spending
Subvenite (Orange) (Lamotrigine) by Owp: FDA Orange Book LOE 2040-05-29, 36 AB generics, $267K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Owp |
| FDA Application & Pathway | N218879 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2040-05-29 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 36 |
| 2024 CMS Total Public Spend | $267K |
| 2024 Medicare Part D Spend | $49K |
| 2024 Medicaid Spend | $217K |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 19.1% 2-yr change) |